Get the Daily Brief
Latest Biotech News
Bayer’s asundexian cuts secondary stroke risk — bleeding unchanged
Bayer disclosed Phase 3 results showing its Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by about 26% versus control without increasing bleeding rates. The company...
Adaptive Biotechnologies projects MRD growth as ClonoSeq adoption rises
Adaptive Biotechnologies forecasted robust growth for its minimal residual disease (MRD) business in 2026, projecting at least 20% year‑over‑year revenue expansion driven by wider adoption of its...
Illumina leans into clinical sequencing — small M&A adds optionality
Illumina reported a Q4 revenue uptick driven by clinical sequencing consumables and disclosed a $50 million purchase of short‑read sequencing-by-binding IP from PacBio to broaden strategic...
Priovant’s brepocitinib posts strong Phase 2 results in cutaneous sarcoidosis
Roivant spinout Priovant Therapeutics reported Phase 2 data showing its TYK2/JAK1 inhibitor brepocitinib significantly outperformed placebo in a small trial for cutaneous sarcoidosis, delivering...
Generate files for IPO after rapid AI-driven progress
Generate: Biomedicines, a Flagship Pioneering‑backed AI-driven drug developer, filed for an initial public offering after rapidly advancing programs and dosing its first Phase 3 patient. The S‑1...
AI-native drugmakers scale: Latent Labs, Formation Bio press design-to-clinic edge
Startups are sharpening AI-first models to accelerate biologics and clinical development. Latent Labs, formed by ex-DeepMind scientists, is marketing AI models that output drug-like biologics...
uniQure pauses dosing after liver toxicities: Fabry gene therapy trial hit
uniQure halted mid- and high-dose cohorts in its AAV gene therapy trial for Fabry disease after two patients experienced dose-limiting toxicities including grade 3 liver enzyme elevations. The...
Hims sells compounded Wegovy pill...FDA warns and makers threaten suits
Telehealth company Hims & Hers began offering a compounded version of Novo Nordisk’s newly approved Wegovy oral formulation, prompting public rebukes and legal threats from Novo and enforcement...
Biotech IPO wave returns: Eikon and Agomab/SpyGlass raise hundreds of millions
Eikon Therapeutics priced an upsized IPO that will raise roughly $381 million to advance its cancer drug candidates, while Agomab Therapeutics and SpyGlass Pharma together raised about $350...
Priovant’s brepocitinib posts strong Phase 2 results — rare skin disease responds
Priovant Therapeutics, a Roivant spinout supported by Pfizer‑origin assets, reported that brepocitinib significantly outperformed placebo in a Phase 2 trial for cutaneous sarcoidosis. The...
Bayer’s asundexian cuts recurrent stroke risk 26% — Phase 3 surprise
Bayer revealed Phase 3 results showing the oral Factor XIa inhibitor asundexian reduced secondary ischemic stroke by 26% without increasing bleeding, according to company disclosures and...
Adaptive Biotechnologies projects MRD boom: ClonoSeq adoption fueling 2026 growth
Adaptive Biotechnologies raised its 2026 outlook, forecasting at least 20% revenue growth in its minimal residual disease (MRD) business driven by adoption of its ClonoSeq assay and expanded use...
Insilico advances AI‑designed NLRP3 inhibitor...company touts global partnerships
Insilico Medicine announced ISM5059, a peripheral‑restricted NLRP3 inhibitor, as its nominated preclinical candidate and highlighted its presence at WHX 2026 to showcase partnerships bridging the...
Novel gene‑editing and neoantigen T‑cell platforms advance personalized cancer approaches
Researchers at Spain’s CNIO and CIEMAT described a CRISPR‑based gene‑editing technique that targets tumors with amplified oncogenes, exploiting copy‑number vulnerabilities to selectively impair...
Mussel‑inspired bioadhesive patch attacks glioblastoma cells — new local therapy
Scientists developed a mussel‑inspired bioadhesive patch that selectively targets and eliminates glioblastoma cells in preclinical models, offering a novel local therapeutic approach for an...
AI‑native drugmakers scale: Formation Bio builds clinical engine — Latent Labs designs biologics
Formation Bio outlined its AI‑native, hub‑and‑spoke model for accelerating clinical development, combining an integrated execution engine and $600M+ of capital to speed trials and regulatory...
Hims pushes compounded Wegovy pill; FDA signals crackdown
Telehealth provider Hims began marketing a compounded, pill-form version of Novo Nordisk’s Wegovy and similar GLP-1 therapies, sparking immediate regulatory and legal pushback. Novo and other...
TrumpRx debuts... limited reach for insured patients
The White House launched TrumpRx, a direct‑to‑consumer drug‑pricing hub built on GoodRx technology that displays cash prices and routes consumers to purchase options. The platform opened with a...
IPO wave returns — Eikon, Agomab, SpyGlass raise fresh capital
Biotech IPO activity accelerated this week with several drug developers tapping public markets. Eikon Therapeutics priced an upsized offering that raised approximately $381 million to advance its...
Generate files for IPO; AI biologics startup gains profile
Generate:Biomedicines filed to go public, positioning its AI‑driven antibody programs — including an anti‑TSLP candidate in Phase 3 — for further clinical funding. The Flagship‑founded company...